Fig. 7: Prognostic significance of immune biomarkers in metastatic tumors.

A Survival analysis of immune biomarkers in metastatic tumors (MTs) and its change status with overall survival (OS). B Forest tree showing the risk of the heterogeneity of immune markers in metastatic NSCLC.